Citations

American Cancer Society (2025) Triple-negative breast cancer: Details, diagnosis, and signs. Details, Diagnosis, and Signs https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html 

Brehmer, D., Beke, L., Wu, T., Millar, H. J., Moy, C., Sun, W., Mannens, G., Pande, V., Boeckx, A., van Heerde, E., Nys, T., Gustin, E. M., Verbist, B., Zhou, L., Fan, Y., Bhargava, V., Safabakhsh, P., Vinken, P., Verhulst, T., … Laquerre, S. (2021). Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity. Molecular Cancer Therapeutics, 20(12), 2317–2328. https://doi.org/10.1158/1535-7163.mct-21-0367 

Cleveland Clinic (2024, October 22) Luminal B Breast Cancer: One of four molecular subtypes. https://my.clevelandclinic.org/health/diseases/luminal-b-breast-cancer 

De Ruijter, T. C., Veeck, J., de Hoon, J. P., van Engeland, M., & Tjan-Heijnen, V. C. (2010). Characteristics of triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology, 137(2), 183–192. https://doi.org/10.1007/s00432-010-0957-x

Hamard, P.-J., Santiago, G. E., Liu, F., Karl, D. L., Martinez, C., Man, N., Mookhtiar, A. K., Duffort, S., Greenblatt, S., Verdun, R. E., & Nimer, S. D. (2018). PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. Cell Reports, 24(10), 2643–2657. https://doi.org/10.1016/j.celrep.2018.08.002

Jerusalem, G., Collignon, J., Schroeder, H., & Lousberg, L. (2016). Triple-negative breast cancer: Treatment challenges and solutions. Breast Cancer: Targets and Therapy, 93. https://doi.org/10.2147/bctt.s69488

Lavogina, D., Krõlov, M. K., Vellama, H., Modhukur, V., Di Nisio, V., Lust, H., Eskla, K.-L., Salumets, A., & Jaal, J. (2024, February 21). Inhibition of epigenetic and cell cycle-related targets in glioblastoma cell lines reveals that Onametostat reduces proliferation and viability in both normoxic and hypoxic conditions. Nature News. https://www.nature.com/articles/s41598-024-54707-4#Sec2

Le Naour, A., Rossary, A., & Vasson, M. (2020). EO771, is it a well‐characterized cell line for Mouse mammary cancer model? limit and uncertainty. Cancer Medicine, 9(21), 8074–8085. https://doi.org/10.1002/cam4.3295 

Li, Z., & Pützer, B. M. (2008). Spliceosomal protein E regulates neoplastic cell growth by modulating expression of cyclin E/cdk2 and G2/M Checkpoint Proteins. Journal of Cellular and Molecular Medicine, 12(6a), 2427–2438. https://doi.org/10.1111/j.1582-4934.2008.00244.

PHC Europe BV. PHC Holdings Corporation (2023). Why use CO2 incubator for cell culture?: Incubation: https://www.phchd.com/eu/biomedical/knowledge-base/why-use-co2-incubator-for-cell-culture 

National Breast Cancer Foundation (2025, July 24) Breast cancer facts & stats 2024 - incidence, age, survival, & more https://www.nationalbreastcancer.org/breast-cancer-facts/ 

U.S. National Library of Medicine. (2025). PRMT5 protein arginine methyltransferase 5 [homo sapiens (human)] - gene - NCBI. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/gene/10419 

Wang, Z., Li, R., Hou, N., Zhang, J., Wang, T., Fan, P., Ji, C., Zhang, B., Liu, L., Wang, Y., Kong, J., Yao, Q., Duan, J., Zhao, G., Ling, R., & Zhang, J. (2023). PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis. Journal for ImmunoTherapy of  Cancer, 11(6). https://doi.org/10.1136/jitc-2023-006890

Walter, V., Fischer, C., Deutsch, T. M., Ersing, C., Nees, J., Schütz, F., Fremd, C., Grischke, E.-M., Sinn, P., Brucker, S. Y., Schneeweiss, A., Hartkopf, A. D., & Wallwiener, M. (2020). Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Research and Treatment, 183(1), 137–144. https://doi.org/10.1007/s10549-020-05746-8